DIACOMIT
What it isGABA-A positive allosteric modulator used with clobazam for Dravet syndrome.
Why this oneIts Dravet-specific role includes deliberately increasing clobazam’s active metabolite through CYP inhibition.
What limits itSomnolence, appetite and weight loss, neutropenia, and interactions are common; clobazam often needs reduction.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Seizures with Dravet syndrome (adjunct with clobazam) | ≥6 months, ≥7 kg | 50 mg/kg/day divided BID or TID | 50 mg/kg/day | 3000 mg/day |
Renal Undefined
Hepatic Undefined
Max 3000 mg/day; do not exceed BID frequency in patients <10 kg (limit free water/overexposure).
Pregnancy No adequate human data; animal developmental toxicity (malformations, mortality) below clinical dose. Enroll in NAAED registry.
Lactation No data on presence in milk or infant effects; weigh benefits/risks.
NO BOXED WARNINGS
Principal riskmarked sedation from increased clobazam and norclobazam exposure
Cost, est. cash$300–$2,500/month
Generic entry2029 est.
Legacy pregnancy categoryNot assigned — PLLR-era drug
Defining liabilitySedation, dizziness and agent-specific rash, behavioral, hepatic, hematologic or teratogenic toxicity.

Open Stiripentol in the interactive console ↗
